Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Prager

Nurse Practitioner, Primary Care Topeka, KS Nurse Practitioner

NPI 1962871202 CMS profile 10452117

901 Sw Garfield Ave, Topeka, KS 66606

Open in the dashboard

General payments

$39,183

124 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Prager of Topeka, KS is reported in the CMS Open Payments database as having received $39,183 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16 1
2024 General $1,428 2
2023 General $34,817 89
2022 General $311 17
2021 General $2,610 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Prager
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Michelle Prager were reported at $16. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Michelle Prager Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,610 $137 $39–$445 $132
2022 $311 $139 $44–$421 $149
2023 $34,817 $163 $53–$481 $160
2024 $1,428 $176 $54–$511 $164
2025 $16 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $17,155 43 payments
  2. Gilead Sciences, Inc. $14,279 44 payments
  3. Pfizer Inc. $6,794 10 payments
  4. AstraZeneca Pharmaceuticals LP $500 1 payment
  5. Daiichi Sankyo Inc. $251 14 payments
  6. Puma Biotechnology, Inc. $133 7 payments
  7. Myriad Genetic Laboratories, Inc. $54 4 payments
  8. Philips Electronics North America Corporation $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,518 16 payments
  2. Travel and Lodging $12,459 32 payments
  3. Consulting Fee $5,075 5 payments
  4. Food and Beverage $2,132 71 payments
Products named General payments · program years 2021–2025
  1. Trodelvy $13,265 38 payments
  2. VERZENIO $11,258 22 payments
  3. IBRANCE $6,794 10 payments
  4. ENHERTU $251 14 payments
  5. NERLYNX $91 5 payments
  6. myRisk Oncology $42 3 payments
  7. Eagle Eye $16 1 payment
  8. myRisk Germline Dna Sequencing Hereditary Cancer And Rearrangement Analysis $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

326

Median for Nurse Practitioner: 389

Drug cost

$289,344

Median for Nurse Practitioner: $21,885

Branded share of claims

37.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibrance Palbociclib Brand 19 $283,465
Methotrexate Methotrexate Sodium Brand 85 $1,927
Hydroxychloroquine Sulfate Generic 45 $1,616
Leflunomide Generic 31 $1,246
Prednisone Generic 66 $344
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 19 $253
Anastrozole Generic 14 $194
Gabapentin Generic 11 $126
Tramadol Hcl Generic 25 $95
Methylprednisolone Generic 11 $77

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$15,713

Medicare's payments for the services billed

Medicare patients

90

Average age 72

Services billed

325

63 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Diabetes 36%
Depression 36%
Osteoporosis 29%
COPD 24%
Ischemic heart disease 22%
Chronic kidney disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record